Clinical trials data
Verbal Learning in cancer trials: 235 registered studies
Every registered cancer study on ClinicalTrials.gov that names Verbal Learning in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered cancer studies name it in an outcome measure
- 235
- Name it in a primary outcome, 33%
- 77 of 235
Tests named in the same studies
- 1
Verbal Fluency136 studies, 40 as a primary outcome
- 2
Trail Making Test121 studies, 36 as a primary outcome
- 3
Digit Span Test66 studies, 18 as a primary outcome
- 4
Symbol Coding32 studies, 14 as a primary outcome
- 5
Stroop Color-Word Test25 studies, 12 as a primary outcome
- 6
Continuous Performance Test13 studies, 6 as a primary outcome
- 7
Category Fluency13 studies, 2 as a primary outcome
- 8
Symbol Scan Task8 studies, 2 as a primary outcome
- 9
Task Switching Test8 studies, 0 as a primary outcome
- 10
Paced Visual Serial Addition Test7 studies, 4 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 0 |
| 2003 | 1 | 1 |
| 2004 | 1 | 0 |
| 2005 | 2 | 2 |
| 2006 | 2 | 1 |
| 2007 | 2 | 0 |
| 2008 | 4 | 2 |
| 2009 | 5 | 2 |
| 2010 | 2 | 0 |
| 2011 | 6 | 2 |
| 2012 | 5 | 2 |
| 2013 | 6 | 3 |
| 2014 | 9 | 3 |
| 2015 | 12 | 5 |
| 2016 | 18 | 4 |
| 2017 | 16 | 6 |
| 2018 | 12 | 3 |
| 2019 | 13 | 6 |
| 2020 | 13 | 5 |
| 2021 | 26 | 9 |
| 2022 | 14 | 5 |
| 2023 | 15 | 4 |
| 2024 | 12 | 3 |
| 2025 | 12 | 0 |
| 2026 | 22 | 8 |
Phases and study sizes
By phase
- Early phase 12 studies, 0 as a primary outcome
- Phase 16 studies, 0 as a primary outcome
- Phase 1/29 studies, 3 as a primary outcome
- Phase 244 studies, 11 as a primary outcome
- Phase 2/31 studies, 0 as a primary outcome
- Phase 335 studies, 13 as a primary outcome
- Phase 45 studies, 2 as a primary outcome
- Not applicable87 studies, 27 as a primary outcome
- Observational46 studies, 21 as a primary outcome
Participants per study
- Phase 272 median, 47 to 120
- Phase 3258 median, 120 to 424
- Not applicable60 median, 30 to 111
- Observational96 median, 50 to 134
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 2 | 43 | 72 | 47 to 120 |
| Phase 3 | 35 | 258 | 120 to 424 |
| Not applicable | 84 | 60 | 30 to 111 |
| Observational | 46 | 96 | 50 to 134 |
When cancer trials measure it
Latest time point of each outcome
- Within a day13 outcomes, 4 as a primary outcome
- Up to 4 weeks14 outcomes, 5 as a primary outcome
- 1 to 3 months31 outcomes, 14 as a primary outcome
- 3 to 6 months52 outcomes, 23 as a primary outcome
- 6 to 12 months61 outcomes, 18 as a primary outcome
- 1 to 2 years29 outcomes, 5 as a primary outcome
- Over 2 years28 outcomes, 7 as a primary outcome
- No duration given7 outcomes, 1 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
228 of the 235 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting58 studies, 18 as a primary outcome
- Not yet recruiting11 studies, 5 as a primary outcome
- Active, not recruiting27 studies, 5 as a primary outcome
- Completed86 studies, 28 as a primary outcome
- Stopped early21 studies, 7 as a primary outcome
- Status unknown32 studies, 14 as a primary outcome
What they test
- Behavioral45 studies, 13 as a primary outcome
- Drug74 studies, 19 as a primary outcome
- Device16 studies, 4 as a primary outcome
- Dietary supplement1 studies, 1 as a primary outcome
- Procedure17 studies, 6 as a primary outcome
- Diagnostic test6 studies, 1 as a primary outcome
- Biological7 studies, 0 as a primary outcome
- Radiation84 studies, 31 as a primary outcome
- Combination product2 studies, 1 as a primary outcome
- Other54 studies, 17 as a primary outcome
- None given19 studies, 8 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States117 studies, 38 as a primary outcome
- Canada41 studies, 10 as a primary outcome
- China23 studies, 8 as a primary outcome
- Germany16 studies, 2 as a primary outcome
- France15 studies, 3 as a primary outcome
- Netherlands15 studies, 2 as a primary outcome
- Spain12 studies, 2 as a primary outcome
- Australia9 studies, 0 as a primary outcome
- Italy9 studies, 3 as a primary outcome
- Denmark7 studies, 4 as a primary outcome
- United Kingdom7 studies, 1 as a primary outcome
- Belgium6 studies, 0 as a primary outcome
44 countries in all. A study with sites in several counts in each; 7 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed cancer studies that name Verbal Learning: 51 of 86, 59%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed cancer studies that name Verbal Learning | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 17, 20% | 776, 10% |
| Results on ClinicalTrials.gov only | 18, 21% | 1,139, 14% |
| A results paper only | 16, 19% | 1,711, 22% |
| Neither | 35, 41% | 4,327, 54% |
The 235 studies
235 studies match. 77 name Verbal Learning in a primary outcome. Median size 80 participants. Median time to the primary outcome: 6 months.
Loading 235 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 that started before 2000 and 1 planned to start after 2026.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 0 |
| 2003 | 1 | 1 |
| 2004 | 1 | 0 |
| 2005 | 2 | 2 |
| 2006 | 2 | 1 |
| 2007 | 2 | 0 |
| 2008 | 4 | 2 |
| 2009 | 5 | 2 |
| 2010 | 2 | 0 |
| 2011 | 6 | 2 |
| 2012 | 5 | 2 |
| 2013 | 6 | 3 |
| 2014 | 9 | 3 |
| 2015 | 12 | 5 |
| 2016 | 18 | 4 |
| 2017 | 16 | 6 |
| 2018 | 12 | 3 |
| 2019 | 13 | 6 |
| 2020 | 13 | 5 |
| 2021 | 26 | 9 |
| 2022 | 14 | 5 |
| 2023 | 15 | 4 |
| 2024 | 12 | 3 |
| 2025 | 12 | 0 |
| 2026 | 22 | 8 |
Library tests named most
Largest condition groups
Phases
Participants
Lead sponsor: industry 14, NIH 4, other 217. Interventional 189, observational 46.
As a primary outcomeSecondary or other outcomeVerbal Learning
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07908147 | Start2027 | PhaseEarly phase 1 | ConditionsCancer | Participants12 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07867886 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants30 | Lead sponsorIndustry | StatusNot yet recruiting | Library tests named
|
| NCT07836478 | Start2026 | PhaseObservational | ConditionsCancer | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07740317 | Start2026 | PhaseObservational | ConditionsCancer | Participants50 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07729969 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants110 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07716800 | Start2026 | PhaseObservational | ConditionsCancer, Delirium, surgery and intensive care | Participants205 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07652476 | Start2026 | PhaseObservational | ConditionsCancer | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07638852 | Start2026 | PhasePhase 2 | ConditionsCancer | Participants58 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07633626 | Start2026 | PhaseObservational | ConditionsDepression and bipolar disorder, Cancer | Participants24 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07587957 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07470606 | Start2026 | PhasePhase 2 | ConditionsCancer | Participants108 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07463781 | Start2026 | PhaseObservational | ConditionsCancer | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07452458 | Start2026 | PhasePhase 3 | ConditionsCancer | Participants398 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07383649 | Start2026 | PhasePhase 2 | ConditionsCancer | Participants28 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07357636 | Start2019 | PhaseObservational | ConditionsCancer | Participants940 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07331077 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants10 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07313709 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants40 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07259434 | Start2026 | PhaseNot applicable | ConditionsCancer, Cardiovascular disease | Participants152 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07248228 | Start2026 | PhasePhase 2 | ConditionsCancer | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07224503 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants56 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07160751 | Start2026 | PhaseObservational | ConditionsCancer | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07147621 | Start2026 | PhaseObservational | ConditionsCancer | Participants120 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07132190 | Start2025 | PhasePhase 2 | ConditionsCancer | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07125209 | Start2026 | PhaseObservational | ConditionsCancer | Participants18 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07083518 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants60 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
Questions, answered from the data
How many cancer trials use Verbal Learning?
235 registered cancer studies on ClinicalTrials.gov name it in an outcome measure, 77 of them in a primary outcome: 31% of the condition's 760 studies with a cognitive outcome, against 11% of all of them. It is the test cancer trials name most.
Which tests do cancer trials use with Verbal Learning?
Verbal Fluency (136 studies), the Trail Making Test (121 studies) and the Digit Span Test (66 studies).
How many participants do phase 2 cancer trials that use Verbal Learning enroll?
Half of the phase 2 studies that name it enroll 72 participants or fewer, and the middle half enroll 47 to 120. 43 of them give a size.
When do cancer trials measure Verbal Learning?
Half of the primary outcomes that name Verbal Learning are measured within 6 months of the start, and the middle half from 13 weeks to 12 months. 76 primary outcomes give a duration.
How many completed cancer trials that use Verbal Learning have reported results?
51 of the 86 completed studies that name it, 59%, have reported results: 35 posted them on ClinicalTrials.gov, 33 have a results paper linked to the registry record, and 17 did both. The other 35 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
The census counts Verbal Learning and Grocery Trip Game as one test family, so this page counts their studies together.
Run Verbal Learning in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.